A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
NCT05556616
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
This study focuses on testing a medicine called modakafusp alfa when used with other treatments. The goal is to check if there are any negative effects from modakafusp alfa when combined with other medicines. The study will also find out the right amount of modakafusp alfa to use with the other treatments. The dose of modakafusp alfa will be slowly increased until the highest amount that does not cause harm is identified. The participants in the study will receive modakafusp alfa through a vein.
This study focuses on testing a medicine called modakafusp alfa when used with other treatments. The goal is to check if there are any negative effects from modakafusp alfa when combined with other medicines. The study will also find out the right amount of modakafusp alfa to use with the other treatments. The dose of modakafusp alfa will be slowly increased until the highest amount that does not cause harm is identified. The participants in the study will receive modakafusp alfa through a vein.
Third Opinion AI Generated Synopsis
Trial Summary
The main aims of this study are to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Participants will be given modakafusp alfa through a vein.
The main aims of this study are to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Participants will be given modakafusp alfa through a vein.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
